Omalizumab Injection
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Food Allergy
Conditions
Food Allergy, Food Allergy in Children
Trial Timeline
Oct 1, 2024 → Dec 1, 2026
NCT ID
NCT06618963About Omalizumab Injection
Omalizumab Injection is a approved stage product being developed by Roche for Food Allergy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06618963. Target conditions include Food Allergy, Food Allergy in Children.
What happened to similar drugs?
1 of 2 similar drugs in Food Allergy were approved
Approved (1) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06618963 | Approved | Recruiting |
Competing Products
17 competing products in Food Allergy